News
After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
9hon MSN
State attorneys general and federal prosecutors alleged Gilead Sciences illegally bankrolled lavish events for prescribers.
Gilead Sciences Inc. closed 9.09% short of its 52-week high of $119.96, which the company achieved on March 10th.
Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...
3h
Zacks Investment Research on MSNGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...
Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...
StockStory.org on MSN1d
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics SegmentAs the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Gilead Sciences Inc. settled for $202 million over illegal kickbacks for HIV drug prescriptions, following Attorney General ...
Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...
1d
Gulf Business on MSNGilead’s Vítor Papão on key partnerships and the role of tech in public healthGilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...
Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results